Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 3474

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 3474
---
 to our existing securityholders, and the resale of the
shares of common stock by White Lion, or the perception that such resales may occur, could cause the price of our securities to fall.

The
purchase price per share of common stock to be paid by White Lion for the shares of common stock that we may elect to sell to White Lion
under the Common Stock Purchase Agreement, if any, will fluctuate based on the market prices of our shares of common stock at the time
we elect to sell shares of common stock to White Lion pursuant to the Common Stock Purchase Agreement. Depending on market liquidity
at the time, resales of such shares of common stock by White Lion may cause the trading price of our shares of common stock to fall.

If
and when we elect to sell shares of common stock to White Lion, sales of newly issued shares of common stock by us to White Lion could
result in substantial dilution to the interests of existing holders of our shares of common stock. Additionally, the sale of a substantial
number of shares of common stock to White Lion, or the anticipation of such sales, could make it more difficult for us to sell equity
or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.

We
may use proceeds from sales of our common stock made pursuant to the Common Stock Purchase Agreement in ways with which you may not agree
or in ways which may not yield a significant return.

74

We
will have broad discretion over the use of proceeds from sales of our shares of common stock made pursuant to the Common Stock Purchase
Agreement and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.
However, we have not determined the specific allocation of any net proceeds among these potential uses, and the ultimate use of the net
proceeds may vary from the currently intended uses. The net proceeds may be used for corporate purposes that do not increase our operating
results or enhance the value of our securities.

The
amount of our future losses is uncertain and our quarterly operating results may fluctuate significantly or may fall below the expectations
of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.

Our
quarterly and annual operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside
of our control and may be difficult to predict, including the following:

    ●
    our
    ability